These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 20532476

  • 1. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials.
    Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G, ADOPT Study Group, RECORD Steering Committee.
    Diabetologia; 2010 Sep; 53(9):1838-45. PubMed ID: 20532476
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol.
    Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, Komajda M, Gubb J, Biswas N, Jones NP.
    Diabetologia; 2005 Sep; 48(9):1726-35. PubMed ID: 16025252
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Coronary heart disease outcomes in patients receiving antidiabetic agents.
    McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM.
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
    [Abstract] [Full Text] [Related]

  • 11. [ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?].
    Scheen AJ.
    Rev Med Liege; 2007 Jan; 62(1):48-52. PubMed ID: 17343130
    [Abstract] [Full Text] [Related]

  • 12. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
    Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, Haffner SM, Levy D, Lachin JM, Berry RA, Heise MA, Jones NP, Freed MI.
    Diabetes Care; 2002 Oct; 25(10):1737-43. PubMed ID: 12351470
    [Abstract] [Full Text] [Related]

  • 13. Rosiglitazone and myocardial infarction in patients previously prescribed metformin.
    Dormuth CR, Maclure M, Carney G, Schneeweiss S, Bassett K, Wright JM.
    PLoS One; 2009 Jun 27; 4(6):e6080. PubMed ID: 19562036
    [Abstract] [Full Text] [Related]

  • 14. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).
    Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, Yu D, Paul G, Holman RR, Zinman B, Diabetes Outcome Progression Trial (ADOPT) Study Group.
    Diabetes Care; 2010 Jan 27; 33(1):177-83. PubMed ID: 19808911
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy.
    Setter SM, Iltz JL, Thams J, Campbell RK.
    Clin Ther; 2003 Dec 27; 25(12):2991-3026. PubMed ID: 14749143
    [Abstract] [Full Text] [Related]

  • 18. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
    Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, Paul G, Jones NP, Aftring RP, Viberti G, Kahn SE, ADOPT Study Group.
    J Clin Endocrinol Metab; 2010 Jan 27; 95(1):134-42. PubMed ID: 19875477
    [Abstract] [Full Text] [Related]

  • 19. Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data.
    Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG, Hamilton WT, Sattar N, Janmohamed S, Holman RR, Pearson ER, Shields BM, Hattersley AT, MASTERMIND Consortium.
    Diabetes Care; 2018 Sep 27; 41(9):1844-1853. PubMed ID: 30072404
    [Abstract] [Full Text] [Related]

  • 20. Reducing the Burden of Diabetes Treatment: A Review of Low-cost Oral Hypoglycemic Medications.
    Vaughan EM, Rueda JJ, Samson SL, Hyman DJ.
    Curr Diabetes Rev; 2020 Sep 27; 16(8):851-858. PubMed ID: 32026779
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.